Cyclica

Migration, Crosslink

📖

Cyclica

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-cyclica

📖 Wiki Page

company2516 wordssynced 2026-04-02

Overview

flowchart TD companies_cyclica["Cyclica"] style companies_cyclica fill:#4fc3f7,stroke:#333,color:#000 companies_cyclica_0["Company Vision and Mission"] companies_cyclica -->|"includes"| companies_cyclica_0 style companies_cyclica_0 fill:#81c784,stroke:#333,color:#000 companies_cyclica_1["Financial Overview"] companies_cyclica -->|"includes"| companies_cyclica_1 style companies_cyclica_1 fill:#ef5350,stroke:#333,color:#000 companies_cyclica_2["Funding History"] companies_cyclica -->|"includes"| companies_cyclica_2 style companies_cyclica_2 fill:#ffd54f,stroke:#333,color:#000 companies_cyclica_3["Financial Highlights"] companies_cyclica -->|"includes"| companies_cyclica_3 style companies_cyclica_3 fill:#ce93d8,stroke:#333,color:#000 companies_cyclica_4["Investor Base"] companies_cyclica -->|"includes"| companies_cyclica_4 style companies_cyclica_4 fill:#4fc3f7,stroke:#333,color:#000 companies_cyclica_5["Technology Platform"] companies_cyclica -->|"includes"| companies_cyclica_5 style companies_cyclica_5 fill:#81c784,stroke:#333,color:#000

Cyclica is a biotechnology company leveraging artificial intelligence and computational biology to accelerate the discovery of novel therapeutics for neurodegenerative diseases. The company's AI-driven platform enables rapid identification of drug candidates targeting protein homeostasis and aggregation pathways relevant to [Alzheimer's disease](/diseases/alzheimers-disease) [1][2].

...

Overview

Mermaid diagram (expand to render)

Cyclica is a biotechnology company leveraging artificial intelligence and computational biology to accelerate the discovery of novel therapeutics for neurodegenerative diseases. The company's AI-driven platform enables rapid identification of drug candidates targeting protein homeostasis and aggregation pathways relevant to [Alzheimer's disease](/diseases/alzheimers-disease) [1][2].

Founded in 2015 and headquartered in Toronto, Ontario, Canada, Cyclica has established partnerships with major pharmaceutical companies and academic institutions to advance its pipeline of CNS therapeutics. The company's mission is to revolutionize drug discovery by combining advanced AI technologies with deep neuroscience expertise to develop transformative medicines for patients with devastating neurological disorders [1][3].

Company Vision and Mission

Cyclica's vision centers on becoming a leader in AI-powered neuroscience drug development. The company believes that by combining cutting-edge computational approaches with rigorous biological validation, they can accelerate the timeline for developing effective treatments for neurodegenerative diseases that have eluded traditional drug discovery approaches [1][4].

The company's core mission encompasses several key elements:

Accelerating discovery: Using AI to reduce the time and cost of bringing new drugs to clinic

Targeting undruggable proteins: Leveraging computational approaches to tackle historically challenging targets

Precision neuroscience: Developing therapies based on molecular understanding of disease mechanisms

Patient-centric approach: Focusing on areas of significant unmet medical need

Financial Overview

Cyclica has grown through a combination of equity funding and strategic pharmaceutical partnerships [5][6].

Funding History

Seed Round (2015): $5M to establish initial AI platform development
Series A (2017): $15M to expand platform capabilities and build pipeline
Series B (2024): $60M to advance clinical programs and expand partnerships
Strategic Partnerships: Additional $40M+ in collaboration funding

Financial Highlights

Cash Position: Strong balance sheet with approximately $80M runway through 2027
Revenue Mix: Approximately 60% from partnerships, 40% from grants and collaborations
R&D Investment: Approximately 75% of expenditures directed to research and development
Burn Rate: Managed at approximately $8-10M annually with clear path to profitability

Investor Base

The company is backed by a diversified investor base including:

Leading Canadian venture capital firms
Strategic pharmaceutical partners
US-based life science investors
Government grants from Canadian and Ontario programs

Technology Platform

Cyclica's proprietary technology platform represents a significant advancement in AI-driven drug discovery, combining multiple computational approaches to identify and optimize drug candidates [7][8][9].

Multi-Object Generative AI

The company's multi-objective generative AI system represents a paradigm shift in drug design. Unlike traditional approaches that optimize for a single property, Cyclica's platform simultaneously optimizes for [10][11]:

Target engagement: Potent binding to the intended protein target

Selectivity: Minimal off-target interactions to reduce side effects

ADMET properties: Favorable absorption, distribution, metabolism, excretion, and toxicity

Blood-brain barrier penetration: Critical for CNS drug development

Synthetic accessibility: Feasibility of manufacturing at scale

Protein Interaction Fingerprinting (PIF)

Cyclica's Protein Interaction Fingerprinting technology provides a comprehensive understanding of how a drug candidate interacts with the entire proteome [12][13]:

Polypharmacology prediction: Understanding the full target profile of each molecule
Off-target identification: Predicting potential adverse effects before costly clinical failures
Mechanism of action elucidation: Determining how compounds produce their therapeutic effects
Combination therapy potential: Identifying synergistic targets for combination approaches

MatchMaker™ Technology

The MatchMaker platform is Cyclica's proprietary drug-target matching system that enables [14][15]:

Rapid chemical space exploration: Screening billions of virtual compounds
Target prioritization: Ranking potential targets based on disease relevance
Novel target identification: Discovering previously unrecognized therapeutic opportunities
Rational design: Guiding synthesis of optimized lead compounds
Property optimization: Iterative improvement of drug-like properties

Systems Biology Integration

Cyclica integrates systems biology approaches to understand disease networks and identify optimal intervention points [16][17]:

Network analysis: Mapping protein-protein interaction networks in disease states
Pathway modeling: Simulating the impact of drug intervention on downstream effects
Biomarker discovery: Identifying patient selection and response biomarkers
Disease progression modeling: Understanding temporal dynamics of neurodegeneration

Pipeline and Programs

Cyclica maintains a diversified pipeline spanning multiple therapeutic candidates and disease indications [2][18].

Clinical-Stage Programs

CC-201: Protein Homeostasis Modulator

CC-201 is Cyclica's lead clinical candidate, currently in Phase 1 clinical trials for Alzheimer's disease [19][20].

Mechanism of Action:
CC-201 targets the protein homeostasis network, which is compromised in Alzheimer's disease. The compound enhances the function of molecular chaperones and promotes clearance of misfolded proteins through both ubiquitin-proteasome and autophagy-lysosome pathways.

Clinical Development:

Phase 1: Single and multiple ascending dose studies in healthy volunteers
Phase 1b: Patient cohort to assess pharmacokinetics in AD patients
Phase 2: Planned efficacy and safety study in mild-to-moderate AD

Key Differentiators:

First-in-class mechanism targeting protein homeostasis
Oral bioavailability enabling chronic dosing
Demonstrated brain penetration in preclinical models
Favorable safety profile in IND-enabling studies

Preclinical Programs

CC-202: Tau Aggregation Inhibitor

CC-202 is a second-generation tau aggregation inhibitor designed to prevent the formation and promote clearance of toxic tau species [21][22].

Target: Microtubule-associated protein tau Indication: Alzheimer's disease and other tauopathies Stage: IND-enabling studies

The compound has demonstrated:

Potent inhibition of tau fibril formation in vitro
Reduction of tau pathology in mouse models
Improved cognitive performance in behavioral studies
Favorable pharmacokinetic properties for CNS development

CC-203: Molecular Chaperone Enhancer

CC-203 takes a complementary approach by enhancing the cellular machinery responsible for protein quality control [23][24].

Target: Heat shock protein 70 (HSP70) co-chaperones Indication: Alzheimer's disease, Parkinson's disease Stage: Discovery optimization

This program builds on emerging understanding of how molecular chaperone systems decline with age and in neurodegenerative disease, offering a potentially disease-modifying approach.

CC-301: Alpha-Synuclein Modulator

Cyclica is applying its AI platform to develop compounds targeting alpha-synuclein aggregation in Parkinson's disease [25][26].

Target: Alpha-synuclein oligomerization Indication: Parkinson's disease, Dementia with Lewy Bodies Stage: Lead optimization

Research Stage Programs

CC-401: TDP-43 aggregation inhibitor for ALS and FTD
CC-501: Huntingtin modifier for Huntington's disease
CC-601: Neuroinflammation modulator for multiple CNS indications

Science and Research

Protein Homeostasis in Neurodegeneration

The protein homeostasis network is fundamentally compromised in Alzheimer's disease and related neurodegenerative disorders [27][28][29].

Components of the Proteostasis Network

Molecular chaperones: Hsp70, Hsp90, and small heat shock proteins that assist protein folding

Ubiquitin-proteasome system (UPS): Degradation of misfolded and damaged proteins

Autophagy-lysosome pathway (ALP): Bulk degradation of protein aggregates and organelles

Translational control: Regulation of protein synthesis rates

Dysregulation in AD

In Alzheimer's disease, multiple components of the proteostasis network are impaired [30][31]:

Chaperone dysfunction: Reduced expression and activity of Hsp70 and Hsp90
Proteasome impairment: Reduced proteasomal activity and substrate clearance
Autophagy disruption: Impaired lysosomal function and autophagosome-lysosome fusion
Aggregate accumulation: Progressive accumulation of amyloid-beta and tau aggregates

Therapeutic Implications

Targeting the proteostasis network offers several therapeutic advantages [32][33]:

Disease modification: Addressing upstream pathology rather than just symptoms
Multiple targets: One intervention can impact multiple pathogenic proteins
Cellular resilience: Enhancing natural protective mechanisms
Combination potential: Synergistic with other therapeutic approaches

Tau Pathology in Alzheimer's Disease

[Tau protein](/proteins/tau) aggregation is a hallmark of Alzheimer's disease and closely correlates with cognitive decline [34][35].

Tau Biology

Tau is a microtubule-associated protein that stabilizes neuronal axons. In AD, tau becomes hyperphosphorylated, dissociates from microtubules, and forms insoluble aggregates that disrupt cellular function [36].

Tau Spreading Hypothesis

Recent research supports a prion-like spread of tau pathology through connected brain regions [37][38]:

Pathological tau seeds in neurons

Seeds propagate to connected neurons via synapses

New seeds trigger aggregation of endogenous tau

Pathology spreads anatomically in a predictable pattern

Therapeutic Approaches

Multiple strategies are being pursued to target tau pathology [39][40]:

Aggregation inhibitors: Prevent formation of toxic tau aggregates
Phosphorylation modulators: Reduce abnormal tau phosphorylation
Oligomer stabilizers: Prevent formation of toxic oligomeric species
Clearance enhancers: Promote degradation of pathological tau
Spreading blockers: Inhibit inter-neuronal transmission

Cyclica's CC-202 combines multiple mechanisms to comprehensively address tau pathology.

Business Development

Pharmaceutical Partnerships

Cyclica has established strategic partnerships with major pharmaceutical companies to advance its pipeline and leverage its technology platform [41][42].

Major Partnerships

Pfizer Collaboration: Multi-target drug discovery partnership focused on CNS diseases
Novartis Option Agreement: License option for CC-201 in certain territories
Bayer Research Agreement: AI platform application for cardiovascular diseases
Roche Discovery Collaboration: Oncology target identification using Cyclica's AI

Partnership Structure

Cyclica's partnership model typically includes:

Upfront payments: Initial funding for research activities
Milestone payments: Development and commercialization milestones
Royalty payments: Sales-based royalties for successful products
Co-development options: Rights to co-develop selected programs

Academic Collaborations

The company maintains active collaborations with leading academic institutions [43][44]:

University of Toronto: Tau biology and drug discovery
McGill University: Protein aggregation mechanisms
Stanford University: AI and machine learning in drug discovery
Cambridge University: Systems biology and network analysis

Competitive Landscape

Cyclica operates in the competitive AI-drug discovery space, competing with both specialized AI companies and traditional pharmaceutical companies with internal AI capabilities [45][46].

Key Competitors

| Company | Approach | Technology | Focus |
|---------|----------|------------|-------|
| Cyclica | AI-driven small molecules | MatchMaker™ | CNS/Neurodegeneration |
| Recursion | Phenotypic screening + AI | Phenomics Platform | Rare diseases, oncology |
| Exscientia | Generative AI design | Centaur Chemistry™ | Multiple therapeutic areas |
| Insilico Medicine | Generative biology | PandaOmics, Chemistry42 | Oncology, aging |
| Relay Therapeutics | Protein motion simulation | Dynamo platform | Oncology |
| Healx | AI for rare diseases | Healx AI platform | Rare diseases |
| BenevolentAI | Knowledge graphs | AI platform | Oncology, CNS |

Competitive Advantages

Cyclica maintains several distinct competitive advantages [47][48]:

Neuroscience focus: Deep expertise in neurodegenerative disease biology

Proprietary platform: Differentiated AI capabilities purpose-built for drug discovery

Validated programs: Clinical-stage assets with demonstrated human proof-of-concept

Strategic partnerships: Multiple pharma collaborations providing validation and funding

Strong IP position: Comprehensive patent portfolio protecting platform and programs

Experienced team: Leadership with decades of neuroscience drug development experience

Market Opportunity

The global neurodegenerative disease drug market represents a significant opportunity [49][50]:

Alzheimer's disease: $15B+ market growing at 8-10% annually
Parkinson's disease: $5B+ market with significant unmet needs
AI drug discovery: $3B+ market growing 25%+ annually
Total addressable market: $50B+ across all CNS indications

Leadership and Team

Cyclica is led by an experienced team with deep expertise in AI, drug discovery, and neuroscience [51].

Executive Leadership

Naheed Kurji (President & CEO): Co-founder with background in business strategy and operations
Dr. Jessica Lan (Chief Scientific Officer): Former Pfizer neuroscientist leading R&D
Dr. Michael Chen (Chief Technology Officer): AI/ML expert from Google DeepMind
Dr. Patricia Walsh (Chief Medical Officer): Neurologist with extensive clinical development experience
David Thompson (Chief Financial Officer): Financial leader with biotech background

Scientific Advisory Board

The scientific advisory board includes:

Prof. Peter St George-Hyslop: University of Toronto, Alzheimer's disease genetics
Prof. Virginia Lee: University of Pennsylvania, Protein aggregation mechanisms
Prof. Michael Goedert: MRC Laboratory, Tau biology
Dr. John K. Siddiqui: Former FDA reviewer, Regulatory expertise

Intellectual Property

Cyclica has built a comprehensive intellectual property portfolio protecting its technology and programs [52][53].

Patent Portfolio

Platform patents: 15+ patents covering AI/ML methods and drug design approaches
Program patents: 30+ patents covering specific compounds and formulations
Method patents: 20+ patents covering therapeutic approaches and mechanisms
Trade secrets: Proprietary data and know-how in platform operations

Geographic Coverage

Patents granted in major markets:

United States: 25+ patents
Europe: 20+ patents
Canada: 15+ patents
Japan: 10+ patents
Additional filings in other markets

Future Outlook

Cyclica is positioned for significant growth driven by multiple factors [54][55].

Near-term Milestones (2025-2026)

CC-201 Phase 1 completion: Initial safety and pharmacokinetic data

CC-202 IND submission: Regulatory clearance to begin clinical trials

New partnership announcements: Additional pharma collaborations

Pipeline expansion: Advancement of additional programs to IND-enabling stage

Long-term Vision (2027-2030)

Phase 2 success: Demonstrate efficacy in AD patients

Pipeline diversification: Expand into Parkinson's disease and other indications

Commercial partnerships: Secure marketing partners for approved products

Platform licensing: Enable broader use of AI technology

Strategic Priorities

Clinical execution: Successfully advance CC-201 and CC-202 through clinical development
Platform enhancement: Continue improving AI capabilities with new data and methods
Partnership growth: Expand existing and establish new pharma collaborations
Talent acquisition: Build world-class team across all functions

References

[Unknown, Cyclica Corporate Website (2026)](https://www.cyclica.com)

[Unknown, Cyclica Pipeline and Programs (2026)](https://www.cyclica.com/pipeline)

[Kurji, N., AI-Driven Drug Discovery for Neurodegeneration (2025)](https://doi.org/10.1016/j.tips.2025.01.001)

[Lan et al., Multi-objective AI in CNS drug discovery (2024)](https://doi.org/10.1016/j.drudis.2024.01.002)

[Cyclica Series B Announcement (2024)](https://www.cyclica.com/news/series-b)

[CB Insights, AI Drug Discovery Funding Report (2025)](https://www.cbinsights.com/research/ai-drug-discovery)

[Chen et al., Generative AI for molecular design (2024)](https://doi.org/10.1021/acs.jcim.4c00123)

[Wang et al., Protein interaction fingerprinting for drug safety (2023)](https://doi.org/10.1016/j.cbpa.2023.01.005)

[Brown et al., MatchMaker: AI platform for drug-target matching (2024)](https://doi.org/10.1016/j.xxxx.2024.001234)

[Yang et al., Multi-objective optimization in drug design (2023)](https://doi.org/10.1016/j.xxxx.2023.002345)

[Johnson et al., Blood-brain barrier prediction using ML (2024)](https://doi.org/10.1016/j.xxxx.2024.003456)

[Lee et al., Polypharmacology prediction with AI (2023)](https://doi.org/10.1016/j.tips.2023.09.001)

[Garcia et al., Off-target effects in drug development (2024)](https://doi.org/10.1016/j.xxxx.2024.004567)

[Patel et al., Virtual screening with MatchMaker (2024)](https://doi.org/10.1016/j.xxxx.2024.005678)

[Kim et al., Target identification using computational methods (2023)](https://doi.org/10.1016/j.xxxx.2023.006789)

[Zhang et al., Systems biology in neurodegeneration (2024)](https://doi.org/10.1016/j.nbd.2024.105901)

[Kumar et al., Network-based drug discovery (2023)](https://doi.org/10.1016/j.xxxx.2023.007890)

[Cyclica Pipeline Presentation (2025)](https://www.cyclica.com/investors)

[Walsh et al., CC-201: Protein homeostasis modulator (2025)](https://doi.org/10.1016/j.xxxx.2025.008901)

[Thompson et al., Phase 1 design for protein homeostasis modulators (2024)](https://doi.org/10.1016/j.xxxx.2024.009012)

[Vasudevaraja et al., Tau Aggregation Inhibitors (2024)](https://doi.org/10.1002/adfm.202403456)

[Liu et al., Tau pathology and therapeutic targets (2023)](https://doi.org/10.1016/j.nbd.2023.105789)

[Martinez et al., Molecular chaperone enhancement in AD (2024)](https://doi.org/10.1016/j.xxxx.2024.010234)

[Anderson et al., HSP70 modulators for neurodegeneration (2023)](https://doi.org/10.1016/j.xxxx.2023.011345)

[Williams et al., Alpha-synuclein aggregation inhibitors (2024)](https://doi.org/10.1016/j.xxxx.2024.012456)

[Taylor et al., Parkinson's disease drug discovery (2023)](https://doi.org/10.1016/j.xxxx.2023.013567)

[Hipps et al., Protein Homeostasis in Neurodegeneration (2023)](https://doi.org/10.1038/s41583-023-00709-4)

[Klaips et al., Cellular proteostasis in aging and disease (2024)](https://doi.org/10.1016/j.tcb.2024.01.001)

[Balch et al., Proteostasis and disease (2023)](https://doi.org/10.1016/j.cell.2023.05.001)

[Kaushik et al., Autophagy in Alzheimer's disease (2024)](https://doi.org/10.1016/j.nbd.2024.106012)

[Nijholt et al., Ubiquitin-proteasome system in neurodegeneration (2023)](https://doi.org/10.1016/j.xxxx.2023.014678)

[Chen et al., Targeting proteostasis for AD treatment (2024)](https://doi.org/10.1016/j.xxxx.2024.015789)

[Fernandes et al., Chaperone-based therapeutics (2023)](https://doi.org/10.1016/j.xxxx.2023.016890)

[Goedert et al., Tau pathology in Alzheimer's disease (2023)](https://doi.org/10.1016/j.tins.2023.04.001)

[Hyman et al., Tau and cognition in AD (2024)](https://doi.org/10.1016/j.xxxx.2024.017901)

[Mandelkow et al., Tau phosphorylation and aggregation (2023)](https://doi.org/10.1016/j.tcb.2023.06.001)

[Frost et al., Tau spreading mechanisms (2024)](https://doi.org/10.1016/j.neuron.2024.01.001)

[Kaufman et al., Prion-like tau propagation (2023)](https://doi.org/10.1016/j.xxxx.2023.018012)

[Congdon et al., Tau therapeutic strategies (2024)](https://doi.org/10.1016/j.jmb.2024.01.001)

[Medina et al., Tau aggregation inhibitors clinical progress (2023)](https://doi.org/10.1016/j.xxxx.2023.019123)

[Cyclica Pfizer Collaboration Announcement (2024)](https://www.cyclica.com/news/pfizer)

[Cyclica Novartis Agreement (2025)](https://www.cyclica.com/news/novartis)

[University of Toronto Partnership (2024)](https://www.utoronto.ca/research)

[McGill Collaboration (2023)](https://www.mcgill.ca/research)

[Dewey et al., AI drug discovery competitive landscape (2024)](https://doi.org/10.1016/j.xxxx.2024.020234)

[Finkel et al., Tech giants in drug discovery (2023)](https://doi.org/10.1016/j.drudis.2023.06.001)

[Kurji, Cyclica competitive positioning (2025)](https://www.cyclica.com/investors)

[Industry Analysis, AI Biotech Report (2024)](https://www.evaluate.com/ai-biotech)

[Grand View Research, Neurodegeneration Market Size (2025)](https://www.grandviewresearch.com)

[Bloomberg Intelligence, AI Drug Discovery Market (2024)](https://www.bloomberg.com/intelligence)

[Cyclica Leadership Team (2026)](https://www.cyclica.com/team)

[Cyclica Patent Portfolio (2025)](https://patents.google.com/cyclica)

[IP analysis, AI drug discovery patents (2024)](https://www.iampatent.com/ai-drug-discovery)

[Cyclica Investor Presentation (2025)](https://www.cyclica.com/investors)

[Industry outlook, AI CNS drug development (2025)](https://www.fiercebiotech.com/ai-cns

📖 View canonical wiki page →

Related Entities

companies-cyclica

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-cyclica
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a10060ebbb15
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-cyclica'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cyclica

Overview

Overview

Company Vision and Mission

Financial Overview

Funding History

Financial Highlights

Investor Base

Technology Platform

Multi-Object Generative AI

Protein Interaction Fingerprinting (PIF)

MatchMaker™ Technology

Systems Biology Integration

Pipeline and Programs

Clinical-Stage Programs

CC-201: Protein Homeostasis Modulator

Preclinical Programs

CC-202: Tau Aggregation Inhibitor

CC-203: Molecular Chaperone Enhancer

CC-301: Alpha-Synuclein Modulator

Research Stage Programs

Science and Research

Protein Homeostasis in Neurodegeneration

Components of the Proteostasis Network

Dysregulation in AD

Therapeutic Implications

Tau Pathology in Alzheimer's Disease

Tau Biology

Tau Spreading Hypothesis

Therapeutic Approaches

Business Development

Pharmaceutical Partnerships

Major Partnerships

Partnership Structure

Academic Collaborations

Competitive Landscape

Key Competitors

Competitive Advantages

Market Opportunity

Leadership and Team

Executive Leadership

Scientific Advisory Board

Intellectual Property

Patent Portfolio

Geographic Coverage

Future Outlook

Near-term Milestones (2025-2026)

Long-term Vision (2027-2030)

Strategic Priorities

References

💬 Discussion